Lexiscan Nuclear Stress Test Market Research Report: Industry Insights, Trends and Forecast up to 2024

Lexiscan or regadenoson is a stress agent, which typically works by increasing blood flow in the arteries of the heart. Lexiscan is specifically used for radionuclide myocardial perfusion imaging (MPI) in patients who are unable to bear adequate exercise stress. In this test, typically, patients are asked to walk on a treadmill or ride a stationary bicycle. The aim is to increase patient’s heart rate until it is adequately stressed.

The heart is a specified muscle and like other muscles in the body it needs oxygen and nutrients so that it can continuously pump blood throughout the body. Regadenoson is injected intravenously in preparation with a radiologic (X-ray) examination of blood flow through the myocardial perfusion imaging (MPI) nuclear stress test or coronary artery test.

On April 10, 2008, Lexiscan was approved by the U.S. Food and Drug Administration (FDA). It is marketed by Astellas Pharma. It is approved in the EU under the name Rapiscan. Currently, it is being marketed by GE Healthcare, which is being sold mainly in the United Kingdom (U.K.) and Germany.

MPI test is taking pictures of the blood flow in a patient’s heart. This test provides detailed anatomical images which can be used to diagnose and evaluate conditions in coronary artery disease. Coronary artery disease progresses when arteries become damaged or diseased. Usually, coronary arteries are damaged when they are accumulated with deposits called plaques. Shortness of breath is a usual indication of coronary artery disease. MPI test images can tell a doctor if a patient’s heart is bloated and can measure its overall functioning, for example ejection fraction.

The choice of lexiscan nuclear stress test modality depends on many factors. Some of the important factors are resting electrocardiogram (ECG), ability to perform exercise, and clinical signals performing the test.

The global lexiscan nuclear stress test market is driven by rise in incidence of coronary heart diseases. According to a recent analysis in the medical journal The Lancet, the number of people with peripheral arterial disease (PAD) has increased by 24% in the past ten years. Globally, millions of people are suffering with heart rhythm disorder atrial fibrillation also called AFib. Currently, nearly 2.7 million people in the U.S. have AFib. This number is expected to increase significantly due to rise in geriatric population. The formation/accumulation of plaque in the arteries in the limbs is one of the major reasons that can cause heart attack or stroke. Other causes of rise in heart diseases are smoking, obesity, and changes in lifestyle. On the other hand, side effects and safety issues related to lexiscan nuclear stress test are projected to restrain the global lexiscan nuclear stress test market. People may experience side effects depending on individual conditions. The most common side effects that followed application of lexiscan test were headache, flushing, chest pain, nausea, feeling hot, dizziness, and nausea. Other factors likely to hamper market growth are rise in cost of overall treatment and surgeries.

View Report-

http://www.transparencymarketresearch.com/lexiscan-nuclear-stress-test-market.html



Key players operating in the lexiscan nuclear stress test market are Astellas Pharma, Inc. and GE Healthcare. Moreover, small number of players operate in this market at the regional level, especially in low to medium income parts of the world.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.



The study is a source of reliable data on:

Market segments and sub-segments

Market trends and dynamics

Supply and demand

Market size

Current trends/opportunities/challenges

Competitive landscape

Technological breakthroughs

Value chain and stakeholder analysis

The regional analysis covers:

North America (U.S. and Canada)

Latin America (Mexico, Brazil, Peru, Chile, and others)

Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)

Eastern Europe (Poland and Russia)

Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)

Middle East and Africa (GCC, Southern Africa, and North Africa)

Request a brochure of this report to know what opportunities will emerge in the rapidly evolving Lexiscan Nuclear Stress Test Market during 2016- 2024

http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=22805

About Us

Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Each TMR syndicated research report covers a different sector – such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMR’s syndicated reports strive to provide clients to serve their overall research requirement.

US Office Contact

90 State Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

This release was published on openPR.